The chart above plots the price of CVS over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 58 sessions over that window: $98.10 on 13 May 2026 through $99.11 on 5 August 2026.
Market cap$126.8B
P/E (TTM)43.5
52-week range$60.01 – $110.58
Avg volume1.7M
Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 11, 2026
CVS insider trades
SEC Form 4 · last 90 days · newest reported trade 21 May 2026
Open-market buys0
Open-market sells3
Net sold$317.47M
Non-trade filings11
DateInsiderTypeSharesValue
21 May 2026ROBBINS LARRYDirectorSell370,462$34.62M
20 May 2026ROBBINS LARRYDirectorSell1,018,000$95.51M
19 May 2026ROBBINS LARRYDirectorSell1,983,538$187.34M
Compensation mechanics
Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.
DateInsiderTypeSharesValue
26 Jun 2026Clark James DavidSVP, Cont & Chief Acct OfficerTax withheld454$41K
31 May 2026Compton-Phillips AmyEVP, Chief Medical OfficerTax withheld7,618$693K
31 May 2026Newman BrianEVP, Chief Financial OfficerTax withheld2,478$225K
21 May 2026AGUIRRE FERNANDODirectorOther1,563$146K
20 May 2026AGUIRRE FERNANDODirectorOther30,437$2.85M
14 May 2026AGUIRRE FERNANDODirectorAward1,563$152K
14 May 2026BROWN C DAVID IIDirectorAward1,544$150K
14 May 2026Balser Jeffrey R.DirectorAward2,058$200K
14 May 2026SANSONE GUY PDirectorAward1,447$141K
14 May 2026Norwalk Leslie VDirectorAward1,447$141K
14 May 2026KIRBY J SCOTTDirectorAward1,447$141K
CVS reported financials
SEC EDGAR XBRL
CVS reported revenue of $402.1B for the fiscal year ended 31 Dec 2025. Net income over the same period was $1.8B.
FigureReportedPeriod
Revenue
$402.1B
31 Dec 2025 fiscal year
Net income
$1.8B
31 Dec 2025 fiscal year
Diluted EPS
$1.39
31 Dec 2025 fiscal year
Total assets
$253.8B
30 Jun 2026 at period end
Total equity
$79.7B
30 Jun 2026 at period end
Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
CVS earnings
SEC EDGAR
DatePeriodEPSRevenue
30 Jun 2026Q2 2026$2.31$106.10B
31 Mar 2026Q1 2026$2.30$100.43B
31 Dec 2025FY 2025$1.39$402.07B
30 Sep 2025Q3 2025$-3.13$102.87B
30 Jun 2025Q2 2025$0.80$98.92B
31 Mar 2025Q1 2025$1.41$94.59B
31 Dec 2024FY 2024$3.66$372.81B
30 Sep 2024Q3 2024$0.07$95.43B
Reported figures & scheduled dates · SEC EDGAR filings
CVS institutional holders
SEC Form 13F
1 of the 45 institutional funds we track reported a CVS position for the quarter ended 30 Jun 2026 — a combined $9.5M; the latest of those filings landed 04 Aug 2026.
On 14 Jul 2026, 461 shares of CVS failed to deliver (about $49K) — the latest of at least 11 consecutive trading days with recorded fails. The run reaches the start of the window we read, so it may have begun earlier.
Settlement dateShares failedNotional% of shares out